Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Di Leo

Showing results (81-90 of 187) with videos related to

Pageof 19
Sort By:
Biomolecular Detection and Quantification|April 15, 2016
Feasibility of a workflow for the molecular characterization of single cells by next generation sequencingFrancesca Salvianti, Giada Rotunno, Francesca Galardi, et al.
Breast Cancer Research and Treatment|July 15, 2009
Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patientsMarta Pestrin, Silvia Bessi, Francesca Galardi, et al.
Future Oncology (London, England)|April 25, 2022
A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ <i>PIK3CA</i>-mutated breast cancerJose Alejandro Pérez-Fidalgo, Carmen Criscitiello, Eva Carrasco, et al.
Breast Cancer Research and Treatment|August 21, 2002
Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testingDavid Gancberg, Tero Järvinen, Angelo di Leo, et al.
Biomolecules|December 18, 2020
Cell-Free DNA-Methylation-Based Methods and Applications in OncologyFrancesca Galardi, Francesca De Luca, Dario Romagnoli, et al.
International Journal of Clinical Oncology|August 31, 2002
Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002Angelo Di Leo, Fatima Cardoso, Virginie Durbecq, et al.
Oncotarget|September 17, 2016
A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancerLuca Malorni, Silvano Piazza, Yari Ciani, et al.
NPJ Breast Cancer|February 13, 2021
Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapiesJohn F R Robertson, Angelo Di Leo, Stephen Johnston, et al.
Clinical Breast Cancer|December 9, 2004
Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancerFatima Cardoso, Marianne Paesmans, Denis Larsimont, et al.
Plos One|May 14, 2013
The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept studyJustin Stebbing, Rachel Payne, Justine Reise, et al.
Pageof 19

Showing results (81-90 of 187) with videos related to

Sort By:
Pageof 19
Biomolecular Detection and Quantification|April 15, 2016
Feasibility of a workflow for the molecular characterization of single cells by next generation sequencingFrancesca Salvianti, Giada Rotunno, Francesca Galardi, et al.
Breast Cancer Research and Treatment|July 15, 2009
Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patientsMarta Pestrin, Silvia Bessi, Francesca Galardi, et al.
Future Oncology (London, England)|April 25, 2022
A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ <i>PIK3CA</i>-mutated breast cancerJose Alejandro Pérez-Fidalgo, Carmen Criscitiello, Eva Carrasco, et al.
Breast Cancer Research and Treatment|August 21, 2002
Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testingDavid Gancberg, Tero Järvinen, Angelo di Leo, et al.
Biomolecules|December 18, 2020
Cell-Free DNA-Methylation-Based Methods and Applications in OncologyFrancesca Galardi, Francesca De Luca, Dario Romagnoli, et al.
International Journal of Clinical Oncology|August 31, 2002
Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002Angelo Di Leo, Fatima Cardoso, Virginie Durbecq, et al.
Oncotarget|September 17, 2016
A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancerLuca Malorni, Silvano Piazza, Yari Ciani, et al.
NPJ Breast Cancer|February 13, 2021
Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapiesJohn F R Robertson, Angelo Di Leo, Stephen Johnston, et al.
Clinical Breast Cancer|December 9, 2004
Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancerFatima Cardoso, Marianne Paesmans, Denis Larsimont, et al.
Plos One|May 14, 2013
The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept studyJustin Stebbing, Rachel Payne, Justine Reise, et al.
Pageof 19